ERT, a global technology-driven provider of health outcomes services, has decided to acquire invivodata, a provider of electronic Patient Reported Outcomes (ePRO) solutions and consulting services, based in Pittsburgh, Penn.

The transaction was facilitated by the San Francisco-based private equity group, Genstar Capital, which last week completed its acquisition of ERT. The invivodata acquisition immediately positions ERT as a leader in clinical outcome assessments (COA). The combined organization will now offer sponsors, CROs and other third-party vendors a combination of market-leading electronic patient reported outcomes (ePRO)/COA solutions and scientific and regulatory consulting services that is unrivalled in the industry.

The invivodata consulting group bolsters ERT’s position in health outcomes research and complements its market leading position in cardiac safety and respiratory outcomes assessment. The acquisition also enhances ERT’s multi-mode ePRO product portfolio with the introduction of a suite of proven site-based and patient-friendly handheld devices that have already been validated to collect therapy-specific diaries, instruments and assessments.

“For some time, ERT has been working in collaboration with sponsors and partners to establish a new model of delivering value through the centralization of health outcomes data,” said Jeffrey Litwin, CEO of ERT. “By adding invivodata’s team of scientists and technology experts, we accelerated this strategic initiative, which will provide our joint clients with consistent, scientifically accurate outcome assessment data which will be accessible from one platform.”